Therefore, it can be deduced that 4-AAQB ameliorated NAFLD through the inhibition of ERS/NLRP3 inflammasome by activating SIRT1-the Nrf2 pathway, which needs to be further verified. The gene discussed is NFE2L2; the disease is metabolic dysfunction-associated steatotic liver disease.